King's College London

Research portal

Inhaled corticosteroids prescribed for COPD patients with mild or moderate airflow limitation: who warrants a trial of withdrawal?

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)3063-3066
Number of pages4
JournalInternational journal of chronic obstructive pulmonary disease
Early online date3 Jan 2020
Publication statusE-pub ahead of print - 3 Jan 2020

King's Authors


COPD patients prescribed inhaled corticosteroids (ICS) outside guidelines should be targeted for ICS withdrawal. Within a primary care population of 209,618 we used a combination of digital search algorithm, individual record review, and clinical review to identify COPD patients suitable for a trial of ICS withdrawal. At most, 39% of COPD patients with mild or moderate airflow limitation prescribed ICS were suitable for withdrawal according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Recurrent exacerbations and reversible airways obstruction were the main reasons for patients’ unsuitability for withdrawal. Identifying COPD patients in whom ICS withdrawal should be considered presents a challenge to primary care clinicians.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454